Page last updated: 2024-10-29

avapro and Dyslipidemias

avapro has been researched along with Dyslipidemias in 1 studies

Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.
irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.

Dyslipidemias: Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Rizos, CV1
Liberopoulos, EN1
Tellis, K1
DiNicolantonio, JJ1
Tselepis, AD1
Elisaf, MS1

Trials

1 trial available for avapro and Dyslipidemias

ArticleYear
Combining rosuvastatin with angiotensin-receptor blockers of different PPARĪ³-activating capacity: effects on high-density lipoprotein subfractions and associated enzymes.
    Angiology, 2015, Volume: 66, Issue:1

    Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Angiotensin II Type 1 Receptor Blockers; Aryld

2015